Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Spinal fractures

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Spinal fractures. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-002143-27 Sponsor Protocol Number: 73950 Start Date*: 2021-02-09
    Sponsor Name:Maasstad Ziekenhuis
    Full Title: Spinal morphine in patients with hip fractures to reduce delirium
    Medical condition: Proximal femur fracture
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10017322 Fractures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001376-12 Sponsor Protocol Number: BISMARK 2005 Start Date*: 2005-08-19
    Sponsor Name:University of Sheffield
    Full Title: Cost-effective use of BISphonphonates in metastatic bone disease - a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule.
    Medical condition: Advanced breast cancer with bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011920-69 Sponsor Protocol Number: 0822-043-00 Start Date*: 2011-08-05
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Quantitative Computed Tomography (QCT) Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fra...
    Medical condition: postmenopausal osteoporosis
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2022-003178-22 Sponsor Protocol Number: 91255 Start Date*: 2022-11-16
    Sponsor Name:Unknown at this point Between jobs [...]
    1. Unknown at this point Between jobs
    2. Unknown at this point Between jobs
    Full Title: Intrathecal morphine versus sufentanil in ultra-low dose of isobaric bupivacaine in the management of postoperative pain in patients with hip fractures
    Medical condition: Patients Habile
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10041537 Spinal anaesthesia (all forms) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005712-22 Sponsor Protocol Number: 01-2020 Start Date*: 2021-07-08
    Sponsor Name:Gedeon Richter Ibérica
    Full Title: Prospective, randomized, multicenter study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and / or...
    Medical condition: Osteoporosis in postmenopausal women at increased risk of fracture.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10031290 Osteoporotic fracture PT
    Population Age: Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002693-66 Sponsor Protocol Number: 0822-018 Start Date*: 2007-11-13
    Sponsor Name:MERCK SHARP & DOHME CORP.
    Full Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D an...
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Elderly Gender: Female
    Trial protocol: LT (Completed) DK (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) DE (Completed) FR (Prematurely Ended) BE (Prematurely Ended) LV (Completed) EE (Completed) IT (Completed) ES (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019216-20 Sponsor Protocol Number: AZ2010 Start Date*: 2010-05-01
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: "Effects of drug treatment with bisphosphonates (zoledronic acid) in the prevention of skeletal events in breast cancer patients with osteoporosis. Significant correlation with some biological para...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002587-33 Sponsor Protocol Number: MK-0822-018 Start Date*: 2015-01-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: An Open-Label 5-Year 2nd Extension to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteopor...
    Medical condition: osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005258-29 Sponsor Protocol Number: B3D-MC-GHCY Start Date*: 2006-04-12
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: The Effect of Teriparatide Compared with Risedronate on Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures
    Medical condition: chronic back pain and osteoporotic vertebral fracture(s)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003770-23 Sponsor Protocol Number: MO19631 Start Date*: 2006-04-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, controlled study to compare the efficacy of oral ibandronate treatment versus intravenous zoledronate in patients with symptomatic Multiple Myeloma
    Medical condition: Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Prematurely Ended) AT (Prematurely Ended) LV (Prematurely Ended) SI (Prematurely Ended) HU (Prematurely Ended) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005514-10 Sponsor Protocol Number: 0822-018 Start Date*: 2012-03-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduc...
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Elderly Gender: Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002113-39 Sponsor Protocol Number: BAY88-8223/16298 Start Date*: 2014-10-29
    Sponsor Name:Bayer AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ...
    Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000608-42 Sponsor Protocol Number: ISRCTN79831382/NovartisCZOL446G2408 Start Date*: 2004-11-19
    Sponsor Name:University of Sheffield
    Full Title: A randomised study to determine whether zoledronic acid adds to the benefits of chemotherapy and/or hormone therapy in the treatment of women with breast cancer. –AZURE STUDY–
    Medical condition: Stage II/III primary breast cancer, with T stage ≥ T1
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002114-23 Sponsor Protocol Number: BAY88-8223/17096 Start Date*: 2015-10-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus whe...
    Medical condition: Metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002122-67 Sponsor Protocol Number: 1211 Start Date*: 2013-12-05
    Sponsor Name:EORTC
    Full Title: Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration.
    Medical condition: metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003951-44 Sponsor Protocol Number: ΕΑΕ-2017/ΜΜ01 Start Date*: 2017-12-15
    Sponsor Name:Hellenic Society of Hematology
    Full Title: A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and /or Refractory Multiple M...
    Medical condition: Relapsed and /or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000346-33 Sponsor Protocol Number: D361BC00001 Start Date*: 2020-07-20
    Sponsor Name:AstraZeneca AB
    Full Title: Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients with DeNovo Metastatic Ho...
    Medical condition: Metastatic Hormone-Sensitive Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned) BG (Trial now transitioned) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) SK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004091-34 Sponsor Protocol Number: CCR3972 Start Date*: 2014-03-26
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Institute of Cancer Reseacrh
    Full Title: A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer
    Medical condition: Metastatic Castration- Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-001511-22 Sponsor Protocol Number: 004 Start Date*: 2005-08-24
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A 5-Year Open Label Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in the Treatment of Postmenopausal W...
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004578-42 Sponsor Protocol Number: 0822-032 Start Date*: 2008-10-29
    Sponsor Name:Merck & Co. Inc.
    Full Title: An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmeno...
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017082 Fracture due to osteoporosis LLT
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Elderly Gender: Female
    Trial protocol: DK (Completed) CZ (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 17:06:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA